Head-to-head evidence
exidavnemab vs UCB7853
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline
exidavnemab
Developed by BioArctic AB
NCT06671938 · Phase 2 · completed
This is a randomized, double-blind, placebo-controlled trial, but it enrolled only 38 participants split across dose cohorts, its primary endpoint measures adverse-event incidence rather than efficacy, and results have not yet been posted, so no conclusion about benefit can be drawn.
UCB7853
Developed by UCB
NCT04651153 · Phase 1 · completed
This was a randomized, quadruple-blind, placebo-controlled study, a sound design for an early safety trial that included both healthy volunteers and Parkinson's disease patients, but its only endpoints were safety-related, and results are not yet posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: exidavnemab's landscape · UCB7853's landscape